ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
38.14
-0.34%
US Tech 100
19,398.40
0.40%
S&P 500
5,727.73
0.16%
US Dollar vs CAD
1.34446
-0.63%
Bitcoin
63,832.10
0.80%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. CASI Pharmaceuticals Inc (CASI)

  7. CASI Pharmaceuticals Inc (CASI) News

CASI

CASI Pharmaceuticals (CASI)

CASI Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:CASI
DateTimeSourceHeadlineSymbolCompany
09/12/20246:30AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CASICASI Pharmaceuticals Inc
09/04/20247:00AMPR Newswire (US)CASI PHARMACEUTICALS TO PARTICIPATE IN THE 2024 H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCENASDAQ:CASICASI Pharmaceuticals Inc
09/03/202411:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CASICASI Pharmaceuticals Inc
08/29/20247:00AMEdgar (US Regulatory)Form F-3/A - Registration statement by foreign private issuers: [Amend]NASDAQ:CASICASI Pharmaceuticals Inc
08/16/20244:01PMEdgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:CASICASI Pharmaceuticals Inc
08/16/20247:30AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CASICASI Pharmaceuticals Inc
08/16/20247:00AMPR Newswire (US)CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2024 BUSINESS AND FINANCIAL RESULTSNASDAQ:CASICASI Pharmaceuticals Inc
08/14/20245:18AMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:CASICASI Pharmaceuticals Inc
07/19/20244:30PMPR Newswire (US)CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTASNASDAQ:CASICASI Pharmaceuticals Inc
07/19/20245:07AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CASICASI Pharmaceuticals Inc
07/15/20243:01PMEdgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:CASICASI Pharmaceuticals Inc
07/08/20246:48AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CASICASI Pharmaceuticals Inc
07/08/20246:30AMPR Newswire (US)CASI Pharmaceuticals announces appointment of Daniel Lang, MD as CFO and SVPNASDAQ:CASICASI Pharmaceuticals Inc
06/26/20243:15PMPR Newswire (US)CASI Pharmaceuticals Announces Plan To Submit IND Application For CID-103, an Anti-CD 38 Antibody in Antibody-Mediated Rejection, and Receipt of a Non-Binding Proposal to Acquire Entire China Business of the CompanyNASDAQ:CASICASI Pharmaceuticals Inc
06/26/20243:10PMPR Newswire (US)CASI Pharmaceuticals Announces $15 Million Private Placement Financing by Venrock Healthcare Capital Partners, Foresite Capital, Panacea Venture and Dr. Wei-Wu HeNASDAQ:CASICASI Pharmaceuticals Inc
05/15/20247:00AMPR Newswire (US)CASI Pharmaceuticals Receives FDA Clearance On The Investigational New Drug (IND) Application For CID-103 In Immune Thrombocytopenia (ITP)NASDAQ:CASICASI Pharmaceuticals Inc
05/15/20245:50AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CASICASI Pharmaceuticals Inc
05/14/20247:00AMPR Newswire (US)CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2024 BUSINESS AND FINANCIAL RESULTSNASDAQ:CASICASI Pharmaceuticals Inc
05/12/202411:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CASICASI Pharmaceuticals Inc
04/08/20244:00PMPR Newswire (US)CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTASNASDAQ:CASICASI Pharmaceuticals Inc
03/28/20246:00AMPR Newswire (US)CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTSNASDAQ:CASICASI Pharmaceuticals Inc
03/05/20246:00AMPR Newswire (US)CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In ChinaNASDAQ:CASICASI Pharmaceuticals Inc
02/16/20246:00AMPR Newswire (US)CASI PHARMACEUTICALS ANNOUNCES FIRST DOSING OF FOLOTYN® IN CHINANASDAQ:CASICASI Pharmaceuticals Inc
11/14/20236:00AMPR Newswire (US)CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2023 BUSINESS AND FINANCIAL UPDATESNASDAQ:CASICASI Pharmaceuticals Inc
11/08/20236:00AMPR Newswire (US)CASI PHARMACEUTICALS ANNOUNCES MARKET APPROVAL OF CNCT19 BY CHINA NMPANASDAQ:CASICASI Pharmaceuticals Inc
08/11/20236:00AMPR Newswire (US)CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 BUSINESS AND FINANCIAL UPDATESNASDAQ:CASICASI Pharmaceuticals Inc
08/01/20236:00AMPR Newswire (US)Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI PharmaceuticalsNASDAQ:CASICASI Pharmaceuticals Inc
07/20/20237:00AMPR Newswire (US)CASI Pharmaceuticals Acquires Global Intellectual Property Rights to Cleave Therapeutics' VCP/P97 Inhibitor CB-5339NASDAQ:CASICASI Pharmaceuticals Inc
05/17/20236:35AMPR Newswire (US)CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTSNASDAQ:CASICASI Pharmaceuticals Inc
04/26/20238:49AMPR Newswire (US)CASI Pharmaceuticals Files Annual Report on Form 20-F for Fiscal Year 2022NASDAQ:CASICASI Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:CASI

Your Recent History

TSX
TIPS
BMO US TIPS Index ETF
COIN
SPYUST
Smarty Pay
USOTC
AXIM
Axim Biotechnologies (QB)
TSXV
RCC.H
Red Rock Capital
NASDAQ
IEI
iShares 3 to 7 Year Trea...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved